echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Bio's KRAS inhibitor approved for clinical use

    Junshi Bio's KRAS inhibitor approved for clinical use

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 28, the CDE official website showed that Junshi Bio's KRAS inhibitor JS116 applied for clinical application in China for the first time


    JS116 is a small-molecule, irreversible covalent inhibitor of KRASG12C with a new structure for the treatment of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC)


    In November 2020, the company signed the "Technology License and Cooperation Agreement" with Chengdu Huajian Future Technology Co.


    Although the world's first KRAS inhibitor was only approved by the FDA in May 2021, based on the excellent potential in this field, there are already many companies deployed, and the competition is quite fierce.


    KRASG12C target details

    From: Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.